Business Wire

CA-TIGO

8.5.2024 15:01:37 CEST | Business Wire | Press release

Share
Tigo Energy Delivers Most Powerful Solar MLPE for High-Wattage and Bifacial Modules

Tigo Energy, Inc. (NASDAQ: TYGO), a leading provider of intelligent solar and energy software solutions, today announced the newest additions to the Tigo Flex MLPE product family, the Tigo TS4-X line. Designed to serve the commercial and industrial (C&I) as well as utility solar markets, Tigo TS4-X products support the latest high-power solar modules, up to 800W. Members of the TS4-X product family feature compatibility with Pure Signal™ technology in Tigo RSS Transmitters and offer a Multi-Factor Rapid Shutdown (MFRS) option with redundant safety signaling for solar systems serving the food and pharmaceutical cold-chain sectors, or other energy-critical applications. The new devices pair with an industry-leading list of third-party solar inverters to deliver design and installation flexibility for solar installers and engineering, procurement, and construction specialists (EPCs).

As Levelized Cost Of Energy (LCOE) continues to drive the large-scale solar sectors, the TS4-X product line gives installers more freedom to deploy the modules that deliver the power and performance for their customer deployments and reduces labor costs with a no-bolt design and no need for additional ground wiring. The new products are the TS4-X-O with optimization and advanced module-level monitoring, the TS4-X-S with advanced monitoring, and the rapid shutdown-only TS4-X-F, all of which feature:

  • 25A Isc rating and 80V maximum input voltage with plug-and-play support for all solar modules up to 800W,
  • new MFRS capability via wired PLC as well as wireless connections for redundant first responder safety and performance assurance in energy-critical applications,
  • the option for selective optimizer deployment,
  • the first-in-its-class capability for field-upgradable monitoring without the need for MLPE hardware replacement, and
  • over-current and over-temperature protection for MLPE devices.

Tigo TS4-X MLPE devices are IEC and UL certified for global acceptance and are compliant with NEC 2017 and 2020 690.12 Rapid Shutdown specifications when installed with the Tigo RSS Transmitter and UL PVRSS-certified inverter or an inverter with a built-in Tigo-certified transmitter. With reliable frame mounting requiring only 10 seconds for installation, TS4-X devices include industry-standard MC4 connectors with an IP68 enclosure rating for maximum durability.

“The installers operating at the cutting edge of solar are pushing the envelope on system output as well as cost, and the TS4-X closes an important gap at the top end of the module performance spectrum,” said Jing Tian, chief growth officer at Tigo Energy. “As the solar industry evolves, Tigo Energy remains at the forefront of providing solutions that empower installers and developers. With safety, versatility, and compatibility at its core, the TS4-X is an advancement in MLPE technology, aligning with Tigo's commitment to innovative software, total quality solar, and customer satisfaction.”

Tigo TS4-X devices work seamlessly with previous TS4 Flex MLPE devices, Tigo Cloud Connect Advanced (CCA) data logging devices, and Tigo RSS Transmitters, and are UL PVRSS certified with hundreds of inverter models from leading manufacturers to deliver safety, versatility, and compatibility. To learn more about the TS4-X product line, visit: https://www.tigoenergy.com/ts4-x. TS4-X products are available for purchase today - contact the Tigo sales team for additional details: https://www.tigoenergy.com/contacts

About Tigo Energy

Founded in 2007, Tigo is a worldwide leader in the development and manufacture of smart hardware and software solutions that enhance safety, increase energy yield, and lower operating costs of residential, commercial, and utility-scale solar systems. Tigo combines its Flex MLPE (Module Level Power Electronics) and solar optimizer technology with intelligent, cloud-based software capabilities for advanced energy monitoring and control. Tigo MLPE products maximize performance, enable real-time energy monitoring, and provide code-required rapid shutdown at the module level. The company also develops and manufactures products such as inverters and battery storage systems for the residential solar-plus-storage market. For more information, please visit www.tigoenergy.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240508108008/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release

Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize

Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release

Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b

LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 07:09:00 CEST | Press release

The deal would be part of a 360° partnership with Randstad involving: Proposed acquisition of USD 500M+ (€469M) business, primarily across Aerospace & Defence, Automotive, Utilities and BFS Five-year IT services partnership to drive AI-enabled transformation for Randstad’s India Global Capability Center Strategic talent MSP to support LTM’s expanding global workforce LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through cen

Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 07:00:00 CEST | Press release

Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye